ELX 02

Drug Profile

ELX 02

Alternative Names: ELX-02; Synthetic aminoglycoside

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Eloxx Pharmaceuticals
  • Class Aminoglycosides; Antifibrotics; Small molecules
  • Mechanism of Action Ribosomal protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I; Rett syndrome; Cystinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis; Duchenne muscular dystrophy; Mucopolysaccharidosis I; Rett syndrome
  • Preclinical Cystinosis

Most Recent Events

  • 08 Jun 2018 The European Cystic Fibrosis Society-Clinical Trial Network (ECFS-CTN) approved the prospective phase II trial protocol for Cystic fibrosis
  • 08 Jun 2018 Pharmacodynamics data from a preclinical trial in Cystic fibrosis released by Eloxx Pharmaceuticals
  • 27 Apr 2018 ELX 02 receives Orphan Drug status for Cystinosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top